3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neoplasm Metastasis
3
Melanoma
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Virus Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Pain
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Insulin-Like Growth Factor I, Resistance To
1
Humoral Hypercalcemia Of Malignancy
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Disease
1
Interventions
Temozolomide
203
Radiotherapy
118
Bevacizumab
93
Radiation
40
Magnetic Resonance Spectroscopy
28
Irinotecan
27
Carmustine
25
Surgical Procedures, Operative
24
Lomustine
21
Erlotinib Hydrochloride
19
Chemotherapy, Adjuvant
18
Carboplatin
17
temsirolimus
13
Drug Therapy
13
O(6)-benzylguanine
12
Nivolumab
12
sargramostim
11
Sirolimus
11
Radiotherapy, Intensity-Modulated
11
Radiotherapy, Conformal
11
Sorafenib
10
Radiosurgery
10
Imatinib Mesylate
10
Everolimus
10
pembrolizumab
9
motexafin gadolinium
9
Vorinostat
9
Thalidomide
8
IL13-PE38
8
Gefitinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioblastoma
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled